Second, the Met66 allele is very common (e.g., 33% of the white population), and given the centrality of Aβ and tau models in AD and in the development of pharmacotherapeutics, the potential influence of variation in BDNF Val66Met on study outcomes should be considered. Here, MAPT is linked to Alzheimer disease.